Katrina Paumier, Phd Email & Phone Number

Stevenage, England, GB

Cambridge, MA, US

Cambridge, MA, US

Jersey City, NJ, US

Serve as the lead for early development/pipeline programs specifically for publications, congress management, and content/resource development and training/education for field and in-house medical teams. Assist in developing pre-launch strategies for Parkinson's disease and rare disease. Support the clinical development of two-phase III clinical trials by.

Brussels, BE

Develop and maintain relationships with Key Opinion Leaders in the Heartland region to support the Neurology portfolio at UCB specifically focused on Epilepsy, Parkinson's Disease and Restless Leg Syndrome. Deliver medical presentations, facilitate the exchange of scientific information, and support clinical research.

Act as a conduit of information about new research developments, clinical trial activities and therapeutic approaches for EMD Serono. Cultivate and maintain relationships with Health Care Providers and present information to internal stakeholders. Work intensively with people at every step of the therapeutic product development process and translate dense.

St. Louis, MO, US

• Coordinated efforts, monitored and facilitated the day-to-day progress toward Core goals in a longitudinal, multi-site clinical study. Effectively managed and implemented changes across an ever-changing and evolving.
• Initiated and led a research project to determine the half-life of alpha-synuclein in human CNS which will help identify a clinical biomarker for target validation in the clinic
• Developed a global REM Behavioral Disorder (RBD) Consortium to provide a trial-ready, well characterized cohort to test preventative strategies for synucleinopathies
• Awarded supplemental funding ($>3M) to implement new initiatives within an ongoing clinical study including incorporating tau PET imaging, increasing visit frequency, and utilizing more sensitive methods to detect.
• Networked within and outside the University to assemble committees to identify solutions to difficult problems including potential unblinding of participants, site probation, and global site expansion
• Successfully organized the annual external advisory and steering committee meetings to solve pending issues within the DIAN study and obtain scientific updates from each of the study’s Cores

East Lansing, MI, US

• At Michican State University, I directed a Translational Neuroscience laboratory investigating the following research interests: (1) to understand the cellular and molecular events that underlie the pathogenesis of.
• Spearheaded an epidemiologic/data mining study in early Parkinson’s patients, demonstrated a disease modifying effect for antidepressants resulting in three publications, and was awarded $2.5M (RO1) from the NIH to.
• Independently initiated and led a translational project resulting in the development of a novel rat model of alpha-synuclein transmission
• Taught a summer graduate lab-based course with a focus on making primary neuronal cultures
• Successfully developed collaborations outside the University and initiated several translational projects with influential scientists within the Neuroscience field
• Performed community outreach and education within the community (brain awareness week, fundraisers, educational presentations, etc.) to help educate the public about Neuroscience and diseases of aging

New York, New York, US

• As a Michael J. Fox Foundation Post Doctoral Fellow at Pfizer, I researched the development of in vitro and in vivo methods to measure autophagy in Parkinson's disease. This position helped me explore and understand.
• Established and managed collaborations across Pfizer and external organizations to support the autophagy project and the Neuroscience portfolio
• Designed a whole-cell phenotypic compound screen with colleagues in the Primary Pharmacology Group (PPG) to identify an early stage compound for a Parkinson's indication
• Utilized inducible cell lines, primary neuronal cultures and a transgenic mouse model to test putative autophagy enhancers as a potential therapeutic strategy for Parkinson's disease
• Worked closely with Pharmacokinetics/Pharmacodynamics colleagues to model compound exposure to guide in vivo efficacy studies
• Characterized a transgenic mouse model of Parkinson’s disease through behavioral testing and biochemical assays

Cincinnati, Ohio, US

For several years, I worked under the direction of Dr. Tim Collier, a renowned leader in the field of neural transplantation. During that time I initiated several projects examining the ability of embryonic stem cells to promote the survival of both host and grafted dopamine cells. My dissertation project investigated the neuroprotective potential of.

Princeton, NJ, US

As part of the Diabetes and Obesity research group at Pfizer Inc. (La Jolla campus), I worked on four different projects to treat obesity and diabetes. I characterized the binding potential of several small molecule candidates identified through high throughput screening (HTS). I also maintained various cell lines using aseptic technique so that we could.

Atlanta, GA, US

During my tenure at Sapphire, I designed, implemented, and facilitated the annual marketing plan for the region. I was responsible for organizing and overseeing the charitable contributions of internal employees. I developed and maintained client relations including: client satisfaction surveys, client development activities, client skills training, and.

Urbana-Champaign, Chicago, And Springfield, IL, US

Neural mechanisms of learning, memory, and motivation

Phd, Neuroscience

Neuroscience

Internship, Cetacean Research

Bachelors Of Science, Psychology

Associates Of Art, Psychology

Diploma